DNA X Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Continuing Operations Revenue Quarterly0.0%Target: Positive scaling post-testing phase
Cash Position from Continuing Operations Quarterly1.2MTarget: Sufficient working capital to scale platform
Watch Items
- DNA X Platform Scaling and Public LaunchTrigger: Transition from limited testing phase to public marketingAction: Monitor user acquisition, trading volume, and commission-based revenue generation.
- Nasdaq Listing ComplianceTrigger: Receipt of Nasdaq Delisting Determination LetterAction: Track progress of the requested hearing and efforts to maintain listing requirements.
- Ticker Symbol TransitionTrigger: Transition from SONM to DNAXAction: Verify completion of the rebranding process on the Nasdaq Capital Market.
Research as of 20 Jun 2026